MiR-455 inhibits the EMT process in pancreatic cancer [44] and hepatocellular carcinoma [47] by modulating the Wnt/β-catenin and STK17B/AKT/GSK-3β/Snail signaling, respectively. Here, GSK3B is linked to pancreatic neoplasm.